Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms

Obesity Reviews

Volumn 19, Issue 12, 2018, Pages 1630-1641

  Lee, P C ^a,b   Ganguly, S ^a,b   Goh, S Y ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Diabetes; mechanism of action; SGLT 2 inhibitors; weight loss

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DAPAGLIFLOZIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; PIOGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT;

BODY COMPOSITION; BODY MASS; BODY WEIGHT LOSS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EVIDENCE BASED PRACTICE; HUMAN; HYPERPHAGIA; KIDNEY FUNCTION; LIPOLYSIS; META ANALYSIS (TOPIC); METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85053920215     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12755     Document Type: Review

References (69)

1. Abdul-Ghani MA, DeFronzo RA. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. J Intern Med 2014; 276: 352–363
2. Ribola FA, Cançado FB, Schoueri JHM et al. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci 2017; 21: 199–211
3. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. Endocrine Disorders 2013; 13: 58
4. Pinto LC, Rados DV, Remonti LR et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr 2015; 7(Suppl 1): A58
5. Storgaard H, Gluud LL, Bennett C et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 2016; 11: e0166125
6. Cai X, Ji L, Chen Y et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis. J Diabetes Investig 2017; 8: 510–517
7. Wang Y, Hu X, Liu X, Wang Z. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Ther Clin Risk Manage 2016; 12: 1113–1131
8. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 2017; 6: e004007
9. Cai X, Yang W, Gao X et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity (Silver Spring) 2018; 26: 70–80
10. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 2016; 6: e009417
11. Bolinder J, Ljunggren O, Johansson L et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014; 16: 159–169
12. Sakai S, Kaku K, Seino Y et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther 2016; 38: 843–862.e9
13. Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582–2592
14. Leiter LA, Yoon KH, Arias P et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015; 38: 355–364
15. Iemitsu K, Iizuka T, Takihata M et al. Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with Ipragliflozin: interim analysis of the ASSIGN-K study. J Clin Med Res 2016; 8: 373–378
16. Yamamoto C, Miyoshi H, Ono K et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 2016; 63: 589–596
17. Nakayama H, Ohtsuka Y, Kawahara M et al. Changes in body composition during SGLT2 inhibitor treatment and their relevance to the improvement of insulin sensitivity. Diabetes Res Clin Pract 2016; 120(Suppl 1): S50–S51
18. Kawata T, Iizuka T, Iemitsu K et al. Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus. J Clin Med Res 2017; 9: 586–595
19. Brown RE, Gupta N, Aronson R. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: a retrospective cohort analysis. Diabetes Technology Therapeutics 2017; 19: 685–691
20. Shatskov A, Rezvani G, Mansfield T. Efficacy and safety of dapagliflozin in patients with type 2 diabetes: outcome by body mass index. Poster presented at the American Diabetic Association 76th Scientific Sessions 2016; New Orleans, Louisiana, USA; 10–14 June 2016
21. Bell KF, Katz A, Sheehan JJ. Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies. Risk Manage Healthcare Policy 2016; 9: 231–241
22. Inagaki N, Goda M, Yokota S et al. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin Pharmacother 2015; 16: 1577–1591
23. Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodiumdependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest 2014; 5: 382–391
24. Osonoi T, Nakamoto S, Saito M et al. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: a subgroup analysis based on patient characteristics. J Diabetes Investig 2018; 9: 341–353
25. Yoo HJ, Hwang SY, Hong HC et al. Association of metabolically abnormal but normal weight (MANW) and metabolically healthy but obese (MHO) individuals with arterial stiffness and carotid atherosclerosis. Atherosclerosis 2014 May; 234: 218–223
26. Pataky Z, Bobbioni-Harsch E, Golay A. Cardio-metabolic profile is influenced by modest modifications of body weight. Rev Med Suisse 2012 Mar 28; 8: 670–672
27. Gerlanc NM, Cai J, Tkacz J, Bolge SC, Brady BL. The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin. Diabetes Metab Syndr Obes 2017; 10: 89–99
28. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128
29. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657
30. Zhang L, Feng Y, List J et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510–516
31. Wilding JPH, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405–415
32. Rosenstock J, Jelaska A, Frappin G et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815–1823
33. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28: 2948–2961
34. Currie CJ, Morgan CL, Poole CD et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523–1534
35. Leiter LA, Yale JF, Chiasson JL et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005; 29: 186–192
36. Cherney DZI, Cooper ME, Tikkanen I et al. Pooled analysis of phase iii trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018; 93: 231–244
37. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962–971
38. Kashiwagi A, Takahashi H, Ishikawa H et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study. Diabetes Obes Metab 2015; 17: 152–160
39. Haneda M, Seino Y, Inagaki N et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther 2016; 38: 66–88.e20
40. Fioretto P, on behalf of the DERIVE Investigators and Study Team. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Presented at: Endocrine Society's 100th Annual Meeting and Expo; March 19, 2018; Chicago, IL
41. Jabbour SA, Frías JP, Guja C et al. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab 2018; 20: 1–5
42. Rosenstock J, Vico M, Wei L et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473–1478
43. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520–526
44. Sarashina A, Koiwai K, Seman LJ et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 2013; 28: 213–219
45. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669–672
46. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650–657
47. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes 2013; 62: 3324–3328
48. Ferrannini E, Baldi S, Frascerra S et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016; 65: 1190–1195
49. Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization. Adipocyte 2017 Dec; 11: 1–8
50. Esterline RL, Vaag A, Oscarsson J, Vora J. SGLT2 inhibitors; clinical benefits by restoration of normal diurnal metabolism? Eur J Endocrinol 2018 Jan 25. pii: EJE-17-0832
51. Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig 2017; 8: 416–427
52. Wilding JPH, Woo V, Rohwedder K et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014; 16: 124–136
53. Devenny JJ, Godonis HE, Harvey SJ et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012; 20: 1645–1652
54. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499–508
55. Polidori D, Sanghvi A, Seeley RJ, Hall KD. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity (Silver Spring) 2016; 24: 2289–2295
56. Garvey WT, Van Gaal L, Leiter LA et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 2018 Feb 13. pii: S0026–0495(18)30041–6
57. Rajeev SP, Roberts CA, Cuthbertson DJ et al. Changes in energy balance during dapagliflozin therapy in type 2 diabetes—the Energize study. Diabetes 2018; 67(Supplement 1) Available at: https://doi.org/10.2337/db18-1163-P
58. SGLT-2 inhibitor empagliflozin effects on appetite and weight regulation. (SEESAW). Available at: https://clinicaltrials.gov/ct2/show/NCT02798744. Accessed 11 July 2018
59. Lundkvist P, Sjöström CD, Amini S et al. Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab 2017; 19: 49–60
60. Lundkvist P, Pereira MJ, Katsogiannos P et al. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab 2017; 19: 1276–1288
61. Hollander P, Bays HE, Rosenstock J et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care 2017; 40: 632–639
62. Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016; 4: 913–921
63. Wing RR, Bolin P, Brancati FL et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145–154
64. Persson F, Nyström T, Jørgensen ME et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab 2018; 20: 344–351
65. Jesudason DR, Pedersen E, Clifton PM. Weight-loss diets in people with type 2 diabetes and renal disease: a randomized controlled trial of the effect of different dietary protein amounts. Am J Clin Nutr 2013; 98: 494–501
66. Cherney D, Lund SS, Perkins BA et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016; 59: 1860–1870
67. Ito D, Shimizu S, Inoue K et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 2017; 40: 1364–1372
68. Shibuya T, Fushimi N, Kawai M et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab 2018; 20: 438–442
69. Tosaki T, Kamiya H, Himano T et al. Sodium-glucose cotransporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes. Intern Med 2017; 56: 597–604